Rationale: Albuterol, a bronchodilator medication, is the first-line therapy for asthma
worldwide. There are significant racial/ethnic differences in albuterol drug response …

Short-acting β2-adrenergic receptor agonists (SABAs) are the most commonly prescribed
asthma medications worldwide. Response to SABAs is measured as bronchodilator drug …

Reversibility of airway obstruction in response to β 2-agonists is highly variable among
asthmatics, which is partially attributed to genetic factors. In a genome-wide association …

Background The primary rescue medication to treat acute asthma exacerbation is the short-
acting β 2-adrenergic receptor agonist; however, there is variation in how well a patient …

Rationale: β2-Agonists are the most common form of treatment of asthma, but there is
significant variability in response to these medications. A significant proportion of this …

Asthma is a chronic respiratory disease that affects 339 million people worldwide and has a
considerable impact on the pediatric population. Asthma symptoms can be controlled by …

Rationale: Inhaled β-agonists are one of the most widely used classes of drugs for the
treatment of asthma. However, a substantial proportion of patients with asthma do not have a …

Asthma is a complex respiratory disease considered as the most common chronic condition
in children. A large genetic contribution to asthma susceptibility is predicted by the clustering …

Background Albuterol is the first-line asthma medication used in diverse populations.
Although DNA methylation (DNAm) is an epigenetic mechanism involved in asthma and …

Asthma is a chronic lung disease that has a high prevalence. The therapeutic intervention of
this disease can be made more effective if genetic variability in patients' response to …